Anokion Announces New Data from the Phase 1 MoveS-it Study Supporting ANK-700 as a Novel, Potential Disease Modifying Treatment for Relapsing-Remitting Multiple Sclerosis | Morningstar

Source: Buzz FX / 18 Sep 2024 02:30:16   America/Chicago